Radiopharm Theranostics (RADX) files Form 6-K on director interests

Radiopharm Theranostics Limited (RADX) submitted a Form 6-K to make U.S. investors aware of two announcements it released to the Australian Securities Exchange on November 25, 2025.

Rhea-AI Filing Summary

Radiopharm Theranostics Limited (RADX) submitted a Form 6-K to make U.S. investors aware of two announcements it released to the Australian Securities Exchange on November 25, 2025. The announcements are titled “Final Director’s Interest Notice - LA” and “Final Director’s Interest Notice - PH,” which typically relate to the final disclosure of a director’s holdings or changes in interests. Copies of these notices are attached to the Form 6-K as exhibits, but the information is furnished rather than filed, meaning it is not automatically incorporated into other U.S. securities law filings unless specifically referenced.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Radiopharm Theranostics Limited (RADX) report in this Form 6-K?

Radiopharm Theranostics Limited reported that it released two announcements to the Australian Securities Exchange titled “Final Director’s Interest Notice - LA” and “Final Director’s Interest Notice - PH,” and attached them as exhibits.

Which exhibits are included with Radiopharm Theranostics Limited’s Form 6-K?

The Form 6-K includes Exhibit 99.1, titled “Final Director’s Interest Notice - LA,” and Exhibit 99.2, titled “Final Director’s Interest Notice - PH.”

Are the attached director interest notices considered filed under U.S. securities laws for RADX?

The company states that this Form 6-K, including the attached notices, is furnished rather than filed and will not be incorporated into other U.S. securities filings unless specifically referenced.

Why did Radiopharm Theranostics (RADX) issue these final director’s interest notices?

The Form 6-K only notes that the company published “Final Director’s Interest Notice - LA” and “Final Director’s Interest Notice - PH” on the Australian Securities Exchange; detailed reasons would be contained in the attached notices themselves.

Does this Form 6-K for RADX disclose any financial results or major transactions?

No, this Form 6-K is administrative in nature and focuses on furnishing director interest notices rather than financial results or major corporate transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/25/2025 - 06:48 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on November 25, 2025 titled:

“Final Director’s Interest Notice - LA”

“Final Director’s Interest Notice - PH”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Final Director’s Interest Notice - LA
99.2		Final Director’s Interest Notice - PH

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: November 25, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3